{
    "title": "111_hr6331",
    "content": "The Act titled \"Generating Antibiotic Incentives Now Act of 2010\" includes provisions for extending exclusivity period for new qualified infectious disease products. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products before approval or licensure. This extension does not apply to supplements or subsequent applications for changes that do not modify the product's structure. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products before approval or licensure. This extension applies to changes that result in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, or a modification to the structure of the product that does not affect safety or effectiveness for drugs, or safety, purity, or potency for biological products. The Secretary will determine if a drug or biological product is a qualified infectious disease product within 30 days of a request. Regulations for this section will be promulgated within 12 months of enactment. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products. Definitions include exclusivity period, qualified infectious disease product, and qualifying pathogen. The Act \"Generating Antibiotic Incentives Now Act of 2010\" defines a qualifying pathogen as resistant gram positive and gram negative pathogens, multi-drug resistant tuberculosis, or any other infectious pathogen identified as a significant threat to public health due to drug resistance. The \"Generating Antibiotic Incentives Now Act of 2010\" defines a qualifying pathogen as resistant gram positive and gram negative pathogens, multi-drug resistant tuberculosis, or any other infectious pathogen identified as a significant threat to public health due to drug resistance. Section 505E of the Federal Food, Drug, and Cosmetic Act applies to drugs or biological products approved after the enactment of this Act. SEC. 4. PRIORITY REVIEW. The Secretary will prioritize the review of qualified infectious disease products for approval or licensure within 6 months of application submission. SEC. 5. FAST TRACK PRODUCT. SEC. 5. FAST TRACK PRODUCT. Amends section 506(a) of the Federal Food, Drug, and Cosmetic Act to include drugs intended for serious or life-threatening conditions or determined as qualified infectious disease products. The Secretary must review and revise FDA guidelines for clinical trials on antibiotic drugs within specified timeframes to incorporate advancements in scientific and medical knowledge and ensure clarity on approval procedures. Key areas for review include animal models, in vitro techniques, surrogate markers, trial design, and delta values. The Secretary is required to submit reports to Congress on the progress of reviewing FDA guidelines for clinical trials on antibiotic drugs, including key areas like infection, in vitro techniques, surrogate markers, trial design, and delta values. Additionally, sponsors of drugs for qualifying pathogens can request written recommendations for nonclinical and clinical investigations before approval. The Secretary can provide written recommendations for nonclinical and clinical investigations needed for approval or licensing of a drug for infectious disease use under specific acts. The Secretary can provide recommendations for investigations required for approval or licensing of a drug for infectious disease use under specific acts. Definitions for biological product, drug, qualifying pathogen, and Secretary are provided in this section."
}